Frederick Chi-Shing Wang, M.D.
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name | Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Lymphocryptovirus | 9 | 2006 | 14 | 1.800 |
Why?
|
| Herpesviridae Infections | 7 | 2006 | 277 | 1.060 |
Why?
|
| Herpesvirus 4, Human | 13 | 2017 | 1041 | 1.010 |
Why?
|
| Macaca mulatta | 9 | 2013 | 2375 | 0.740 |
Why?
|
| Oculomotor Muscles | 4 | 2015 | 371 | 0.650 |
Why?
|
| Epstein-Barr Virus Nuclear Antigens | 5 | 2007 | 150 | 0.630 |
Why?
|
| Tumor Virus Infections | 5 | 2006 | 452 | 0.580 |
Why?
|
| Genome, Viral | 4 | 2006 | 667 | 0.540 |
Why?
|
| Epstein-Barr Virus Infections | 5 | 2013 | 570 | 0.530 |
Why?
|
| Retinal Pigments | 1 | 2015 | 83 | 0.530 |
Why?
|
| Color Vision | 1 | 2015 | 21 | 0.520 |
Why?
|
| Color | 1 | 2015 | 307 | 0.480 |
Why?
|
| Accommodation, Ocular | 1 | 2013 | 48 | 0.470 |
Why?
|
| Exotropia | 2 | 2006 | 55 | 0.460 |
Why?
|
| Mydriatics | 1 | 2013 | 68 | 0.460 |
Why?
|
| Atropine | 1 | 2013 | 244 | 0.460 |
Why?
|
| Pupil | 1 | 2013 | 149 | 0.440 |
Why?
|
| Horner Syndrome | 1 | 2012 | 37 | 0.420 |
Why?
|
| Iris Diseases | 1 | 2012 | 40 | 0.420 |
Why?
|
| Pigmentation Disorders | 1 | 2012 | 101 | 0.410 |
Why?
|
| Esotropia | 2 | 2015 | 91 | 0.340 |
Why?
|
| Light | 1 | 2015 | 1374 | 0.330 |
Why?
|
| Nasopharyngeal Neoplasms | 2 | 2017 | 286 | 0.330 |
Why?
|
| T-Lymphocytes, Cytotoxic | 4 | 2017 | 1821 | 0.330 |
Why?
|
| Ophthalmologic Surgical Procedures | 3 | 2015 | 349 | 0.310 |
Why?
|
| Open Reading Frames | 3 | 2006 | 810 | 0.300 |
Why?
|
| Callithrix | 2 | 2005 | 93 | 0.280 |
Why?
|
| Simian Acquired Immunodeficiency Syndrome | 3 | 2004 | 570 | 0.260 |
Why?
|
| Cell Transformation, Viral | 3 | 2006 | 565 | 0.260 |
Why?
|
| Cytomegalovirus | 2 | 2006 | 732 | 0.240 |
Why?
|
| Host-Pathogen Interactions | 1 | 2013 | 1477 | 0.240 |
Why?
|
| B-Lymphocytes | 5 | 2006 | 4665 | 0.220 |
Why?
|
| Disease Models, Animal | 4 | 2013 | 18029 | 0.220 |
Why?
|
| Postoperative Care | 1 | 2009 | 1486 | 0.210 |
Why?
|
| Immunocompromised Host | 2 | 2004 | 847 | 0.210 |
Why?
|
| Nystagmus, Pathologic | 1 | 2002 | 96 | 0.200 |
Why?
|
| Epitopes, T-Lymphocyte | 5 | 2007 | 880 | 0.180 |
Why?
|
| CD8-Positive T-Lymphocytes | 4 | 2007 | 4479 | 0.180 |
Why?
|
| Antibodies, Viral | 3 | 2005 | 3176 | 0.170 |
Why?
|
| Vision, Binocular | 3 | 2015 | 213 | 0.150 |
Why?
|
| Pupil Disorders | 2 | 2013 | 33 | 0.140 |
Why?
|
| Chlorophyll | 1 | 2015 | 27 | 0.130 |
Why?
|
| Abducens Nerve Diseases | 1 | 2015 | 43 | 0.130 |
Why?
|
| Cell Line, Transformed | 4 | 2007 | 898 | 0.120 |
Why?
|
| Molecular Sequence Data | 7 | 2006 | 18111 | 0.120 |
Why?
|
| Mydriasis | 1 | 2013 | 15 | 0.120 |
Why?
|
| Retinal Cone Photoreceptor Cells | 1 | 2015 | 177 | 0.120 |
Why?
|
| Amino Acid Sequence | 6 | 2006 | 13815 | 0.120 |
Why?
|
| Viral Proteins | 4 | 2007 | 1900 | 0.110 |
Why?
|
| Immunotherapy, Adoptive | 2 | 2017 | 1270 | 0.110 |
Why?
|
| Gene Transfer Techniques | 1 | 1998 | 1224 | 0.110 |
Why?
|
| Antigens, Viral | 3 | 2007 | 1035 | 0.110 |
Why?
|
| Eye Color | 1 | 2012 | 36 | 0.110 |
Why?
|
| Iridocorneal Endothelial Syndrome | 1 | 2011 | 1 | 0.100 |
Why?
|
| Epithelial Cells | 1 | 2004 | 3690 | 0.100 |
Why?
|
| Maximum Tolerated Dose | 1 | 2013 | 892 | 0.100 |
Why?
|
| Myopia | 1 | 2013 | 254 | 0.100 |
Why?
|
| Virus Latency | 2 | 2005 | 358 | 0.100 |
Why?
|
| Strabismus | 1 | 2013 | 287 | 0.080 |
Why?
|
| Animals | 15 | 2015 | 168757 | 0.080 |
Why?
|
| Base Sequence | 4 | 2006 | 12797 | 0.080 |
Why?
|
| Genetic Vectors | 1 | 1998 | 3420 | 0.080 |
Why?
|
| DNA, Viral | 3 | 2004 | 2225 | 0.080 |
Why?
|
| Antigen Presentation | 2 | 2007 | 1284 | 0.070 |
Why?
|
| Rhadinovirus | 1 | 2006 | 37 | 0.070 |
Why?
|
| Amygdala | 1 | 2013 | 1315 | 0.070 |
Why?
|
| Carcinoma | 1 | 2017 | 2375 | 0.060 |
Why?
|
| T-Cell Antigen Receptor Specificity | 1 | 2005 | 87 | 0.060 |
Why?
|
| Herpesvirus 8, Human | 1 | 2007 | 258 | 0.060 |
Why?
|
| Palatine Tonsil | 1 | 2005 | 193 | 0.060 |
Why?
|
| Leukoplakia, Hairy | 1 | 2004 | 8 | 0.060 |
Why?
|
| Bone Neoplasms | 1 | 2017 | 2529 | 0.060 |
Why?
|
| Immunodominant Epitopes | 1 | 2005 | 267 | 0.060 |
Why?
|
| Visual Perception | 1 | 2013 | 1420 | 0.060 |
Why?
|
| Immunocompetence | 1 | 2004 | 137 | 0.060 |
Why?
|
| Seroepidemiologic Studies | 1 | 2005 | 401 | 0.060 |
Why?
|
| Serologic Tests | 1 | 2005 | 374 | 0.060 |
Why?
|
| Alanine | 1 | 2005 | 572 | 0.060 |
Why?
|
| Cell Line | 4 | 2007 | 15997 | 0.050 |
Why?
|
| Replication Origin | 1 | 2002 | 77 | 0.050 |
Why?
|
| Monkey Diseases | 1 | 2002 | 77 | 0.050 |
Why?
|
| Sequence Homology, Amino Acid | 1 | 2007 | 2839 | 0.050 |
Why?
|
| Immunologic Memory | 2 | 2007 | 1348 | 0.050 |
Why?
|
| Diplopia | 2 | 2015 | 200 | 0.050 |
Why?
|
| Glycine | 1 | 2005 | 671 | 0.050 |
Why?
|
| Capsid Proteins | 1 | 2005 | 479 | 0.050 |
Why?
|
| Sequence Homology | 1 | 2002 | 203 | 0.050 |
Why?
|
| Papio | 1 | 2003 | 656 | 0.050 |
Why?
|
| CD4-Positive T-Lymphocytes | 2 | 2005 | 4386 | 0.050 |
Why?
|
| Sequence Homology, Nucleic Acid | 1 | 2002 | 1085 | 0.050 |
Why?
|
| Glaucoma | 1 | 2011 | 1159 | 0.050 |
Why?
|
| Species Specificity | 1 | 2005 | 2478 | 0.050 |
Why?
|
| Liver Neoplasms | 1 | 2017 | 4253 | 0.050 |
Why?
|
| Integrins | 1 | 2005 | 846 | 0.050 |
Why?
|
| Viremia | 1 | 2004 | 736 | 0.050 |
Why?
|
| RNA, Viral | 3 | 2004 | 2902 | 0.050 |
Why?
|
| Sequence Alignment | 1 | 2005 | 2256 | 0.050 |
Why?
|
| Immunity, Cellular | 1 | 2007 | 1607 | 0.050 |
Why?
|
| Cell Culture Techniques | 2 | 2006 | 1678 | 0.050 |
Why?
|
| Histocompatibility Antigens Class I | 3 | 2006 | 1366 | 0.050 |
Why?
|
| Haplorhini | 1 | 2001 | 552 | 0.050 |
Why?
|
| Humans | 19 | 2017 | 744343 | 0.040 |
Why?
|
| Genes, Viral | 1 | 2001 | 718 | 0.040 |
Why?
|
| Conserved Sequence | 1 | 2003 | 1202 | 0.040 |
Why?
|
| Point Mutation | 1 | 2005 | 1623 | 0.040 |
Why?
|
| Postoperative Complications | 1 | 2002 | 15295 | 0.040 |
Why?
|
| Organ Specificity | 1 | 2004 | 2008 | 0.040 |
Why?
|
| Infant | 2 | 2012 | 35136 | 0.040 |
Why?
|
| Histocompatibility Antigens Class II | 2 | 2005 | 1475 | 0.040 |
Why?
|
| Neoplasm Recurrence, Local | 1 | 2017 | 9239 | 0.040 |
Why?
|
| Lymphoproliferative Disorders | 1 | 2002 | 523 | 0.040 |
Why?
|
| Eye Movements | 1 | 2002 | 507 | 0.040 |
Why?
|
| T-Lymphocytes | 2 | 2007 | 10180 | 0.040 |
Why?
|
| Viral Load | 2 | 2004 | 3299 | 0.040 |
Why?
|
| RNA Splicing | 1 | 2002 | 907 | 0.040 |
Why?
|
| CD4 Lymphocyte Count | 1 | 2004 | 2559 | 0.040 |
Why?
|
| HIV Antigens | 1 | 1998 | 347 | 0.040 |
Why?
|
| Gene Deletion | 1 | 2005 | 2751 | 0.040 |
Why?
|
| Diagnosis, Differential | 1 | 2012 | 12959 | 0.040 |
Why?
|
| Enzyme-Linked Immunospot Assay | 1 | 2017 | 130 | 0.040 |
Why?
|
| Cytomegalovirus Infections | 1 | 2003 | 820 | 0.040 |
Why?
|
| Lymphoma, B-Cell | 1 | 2002 | 931 | 0.030 |
Why?
|
| Trans-Activators | 1 | 2006 | 2924 | 0.030 |
Why?
|
| Lymphoma | 1 | 2004 | 1877 | 0.030 |
Why?
|
| Sensory Deprivation | 1 | 2015 | 109 | 0.030 |
Why?
|
| Interleukin-4 | 1 | 1998 | 1147 | 0.030 |
Why?
|
| Evolution, Molecular | 1 | 2002 | 1940 | 0.030 |
Why?
|
| Eyeglasses | 1 | 2015 | 145 | 0.030 |
Why?
|
| HIV Envelope Protein gp120 | 1 | 1998 | 952 | 0.030 |
Why?
|
| Recombination, Genetic | 1 | 1998 | 1586 | 0.030 |
Why?
|
| Lung Neoplasms | 1 | 2017 | 13102 | 0.030 |
Why?
|
| Male | 6 | 2017 | 350118 | 0.030 |
Why?
|
| Infant, Newborn | 1 | 2012 | 25625 | 0.030 |
Why?
|
| Reoperation | 1 | 2002 | 4201 | 0.030 |
Why?
|
| DNA-Binding Proteins | 2 | 2006 | 9648 | 0.020 |
Why?
|
| Gonioscopy | 1 | 2011 | 157 | 0.020 |
Why?
|
| Child | 2 | 2013 | 77709 | 0.020 |
Why?
|
| Scotoma | 1 | 2011 | 139 | 0.020 |
Why?
|
| Child, Preschool | 1 | 2012 | 41006 | 0.020 |
Why?
|
| Trabeculectomy | 1 | 2011 | 160 | 0.020 |
Why?
|
| Cell Proliferation | 1 | 2005 | 10481 | 0.020 |
Why?
|
| Visual Field Tests | 1 | 2011 | 383 | 0.020 |
Why?
|
| Treatment Outcome | 2 | 2006 | 63114 | 0.020 |
Why?
|
| Adolescent | 2 | 2013 | 85781 | 0.020 |
Why?
|
| Nuclear Proteins | 1 | 2003 | 5853 | 0.020 |
Why?
|
| Repetitive Sequences, Amino Acid | 1 | 2007 | 95 | 0.020 |
Why?
|
| Feasibility Studies | 1 | 2017 | 5078 | 0.020 |
Why?
|
| Kidney Transplantation | 1 | 2002 | 4251 | 0.020 |
Why?
|
| Photic Stimulation | 1 | 2013 | 2025 | 0.020 |
Why?
|
| Fluorouracil | 1 | 2011 | 1619 | 0.020 |
Why?
|
| Disease-Free Survival | 1 | 2017 | 6895 | 0.020 |
Why?
|
| Neoplasm Metastasis | 1 | 2017 | 4851 | 0.020 |
Why?
|
| Flow Cytometry | 1 | 2017 | 5974 | 0.020 |
Why?
|
| Magnetic Resonance Imaging | 1 | 2013 | 35421 | 0.020 |
Why?
|
| Intraocular Pressure | 1 | 2011 | 1270 | 0.020 |
Why?
|
| Dipeptides | 1 | 2007 | 409 | 0.020 |
Why?
|
| Pilot Projects | 1 | 2017 | 8324 | 0.010 |
Why?
|
| Immunoglobulin J Recombination Signal Sequence-Binding Protein | 1 | 2003 | 121 | 0.010 |
Why?
|
| RNA, Nuclear | 1 | 2002 | 30 | 0.010 |
Why?
|
| Sequence Deletion | 1 | 2007 | 1526 | 0.010 |
Why?
|
| Viral Matrix Proteins | 1 | 2003 | 186 | 0.010 |
Why?
|
| Visual Acuity | 1 | 2011 | 2530 | 0.010 |
Why?
|
| Immunophenotyping | 1 | 2007 | 1880 | 0.010 |
Why?
|
| Genes, Reporter | 1 | 2006 | 1547 | 0.010 |
Why?
|
| Female | 3 | 2017 | 380194 | 0.010 |
Why?
|
| Virus Activation | 1 | 2003 | 319 | 0.010 |
Why?
|
| Cadherins | 1 | 2005 | 907 | 0.010 |
Why?
|
| Hippocampus | 1 | 2013 | 3675 | 0.010 |
Why?
|
| Green Fluorescent Proteins | 1 | 2006 | 2088 | 0.010 |
Why?
|
| Epitopes | 1 | 2007 | 2571 | 0.010 |
Why?
|
| Immunohistochemistry | 2 | 2005 | 11366 | 0.010 |
Why?
|
| Disease Progression | 1 | 2017 | 13284 | 0.010 |
Why?
|
| Macaca fascicularis | 1 | 2002 | 915 | 0.010 |
Why?
|
| In Situ Hybridization, Fluorescence | 1 | 2006 | 2649 | 0.010 |
Why?
|
| Haplotypes | 1 | 2006 | 2779 | 0.010 |
Why?
|
| Ligands | 1 | 2005 | 3282 | 0.010 |
Why?
|
| Blotting, Western | 1 | 2006 | 5179 | 0.010 |
Why?
|
| In Situ Hybridization | 1 | 2002 | 1950 | 0.010 |
Why?
|
| Virus Replication | 1 | 2006 | 2534 | 0.010 |
Why?
|
| Simian immunodeficiency virus | 1 | 2003 | 846 | 0.010 |
Why?
|
| Cell Nucleus | 1 | 2006 | 2969 | 0.010 |
Why?
|
| Recombinant Proteins | 1 | 2006 | 6622 | 0.010 |
Why?
|
| Fibroblasts | 1 | 2006 | 4161 | 0.010 |
Why?
|
| Aged | 2 | 2017 | 163280 | 0.010 |
Why?
|
| Sequence Analysis, DNA | 1 | 2003 | 4803 | 0.010 |
Why?
|
| Promoter Regions, Genetic | 1 | 2003 | 5867 | 0.010 |
Why?
|
| Middle Aged | 2 | 2017 | 213383 | 0.010 |
Why?
|
| Adult | 2 | 2017 | 214055 | 0.010 |
Why?
|
| Lymph Nodes | 1 | 2002 | 3474 | 0.010 |
Why?
|
| Young Adult | 1 | 2017 | 56430 | 0.010 |
Why?
|
| Cells, Cultured | 1 | 2006 | 19229 | 0.010 |
Why?
|
| Transcription, Genetic | 1 | 2003 | 7722 | 0.010 |
Why?
|
| Prospective Studies | 1 | 2013 | 53288 | 0.010 |
Why?
|
| Gene Expression Regulation | 1 | 2003 | 12072 | 0.000 |
Why?
|
| Time Factors | 1 | 2006 | 40075 | 0.000 |
Why?
|
| Transcription Factors | 1 | 2003 | 12208 | 0.000 |
Why?
|
| Follow-Up Studies | 1 | 2002 | 39050 | 0.000 |
Why?
|